Vir Biotechnology VIR 深 滬
已收盤 05-08 16:00:00 美东时间
9.12
-0.150
-1.62%
華盛通- 最 高9.54
- 今 開9.31
- 成交量 161.17万股
- 最 低 9.11
- 昨 收 9.27
- 總市值 14.70亿
- 52周最高 11.66
- 市盈率 靜 --
- 換手率 1.00%
- 52周最低 4.155
- 委 比 -78.38%
- 總股本 1.61亿
- 歷史最高 141.01
- 量 比 1.02
- 振 幅 4.64%
- 歷史最低 4.155
- 每 手 1
- 風險率 1.79%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Vir Biotechnology shares are trading lower after the company reported a year-over-year decrease in its Q1 sales results.
Vir Biotechnology shares are trading lower after the company reported a year-ov...
05-08 00:39
Earnings Scheduled For May 6, 2026
Companies Reporting Before The Bell • Deluxe (NYSE:DLX) is expected to report q...
05-07 05:03
Vir Biotechnology announces annual shareholder meeting
Vir Biotechnology announces annual shareholder meeting Vir Biotechnology scheduled 2026 annual stockholder meeting for May 26, 2026, to be held online. Shareholders will vote on election of three Class I directors: Robert More, Janet Napolitano, Elliott Sigal. Advisory vote set on named executive of
04-16 20:48
Vir Biotech Doses First Patient In Phase 1 Expansion Trial Of VIR-5500 For Metastatic Prostate Cancer
Phase 1 trial designed to assess the safety, pharmacokinetics and preliminary efficacy of VIR-5500 in both early and late-line metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive
04-13 20:07
Vir Biotechnology Announces Upcoming Chief Medical Officer Transition
Vir Biotechnology ( ($VIR) ) has provided an announcement. Vir Biotechnology, I...
04-11 04:47
医药生物周报：TCE或将下一个BD风口，建议关注泽璟制药-U、康诺亚、德琪医药等【东吴医药朱国广团队】
投资要点 本周、年初至今A股医药指数涨跌幅分别为-1.26%、-1.38%，相对沪深300的超额收益分别为2.31%、1.37%；本周、年初至今恒生生物科技指...
03-29 21:59
美股大行评级 | 7家上调，3家下调！CrowdStrike绩后大行评级现分歧；罗斯百货、塔吉特、Viking获多家大行上调目标价
今日重点评级关注：古根海姆：维持Dianthus Therapeutics"买入"评级，目标价从100美元升至200美元；HC Wainwright & Co.：维持Amylyx Pharmaceuticals"买入"评级，目标价从28美元升至34美元
03-05 13:56
AI赋能智能监测、生物材料突破革新 标普生物科技ETF嘉实涨2.08%
截至3月5日10点48分，上证指数涨0.78%，深证成指涨1.63%，创业板指涨2.41%。MicroLED概念、光学光电子、电子纸等板块涨幅居前。 ETF方面...
03-05 10:57
Semtech To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Wednesday
Wall Street analysts changed outlook on top names. For full view of changes, including upgrades/downgrades, see analyst ratings page.
03-04 20:35
HC Wainwright & Co. Maintains Buy on Vir Biotechnology, Raises Price Target to $20
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Vir Biotechnology (NASDAQ:VIR) with a Buy and raises the price target from $15 to $20.
03-04 20:02
